Skip to main content

Royalty Pharma PLC (RPRX)

NASDAQ: RPRX · IEX Real-Time Price · USD
37.50 0.00 (0.00%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap22.72B
Revenue (ttm)2.24B
Net Income (ttm)971.62M
Shares Out409.34M
EPS (ttm)1.24
PE Ratio30.36
Forward PE14.97
Dividend$0.64 (1.71%)
Ex-Dividend DateNov 18, 2021
Volume1,064,643
Open37.57
Previous Close37.50
Day's Range37.22 - 37.86
52-Week Range34.25 - 52.59
Betan/a
AnalystsBuy
Price Target51.43 (+37.1%)
Est. Earnings DateNov 10, 2021

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies an...

IndustryPharmaceuticals
IPO DateJun 16, 2020
Employees51
Stock ExchangeNASDAQ
Ticker SymbolRPRX
Full Company Profile

Financial Performance

In 2020, Royalty Pharma's revenue was $2.12 billion, an increase of 16.98% compared to the previous year's $1.81 billion. Earnings were $975.04 million, a decrease of -58.48%.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Royalty Pharma stock is "Buy." The 12-month stock price forecast is 51.43, which is an increase of 37.15% from the latest price.

Price Target
$51.43
(37.15% upside)
Analyst Consensus: Buy

News

Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U...

4 days ago - GlobeNewsWire

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinar...

1 week ago - GlobeNewsWire

Top 3 undervalued US biotech stocks to buy

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a ...

Other symbols:REGNSAGE
1 week ago - Invezz

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

1 month ago - GlobeNewsWire

Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma

Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors.

2 months ago - Benzinga

Royalty Pharma (RPRX) Q2 Earnings and Revenues Surpass Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.43% and 0.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Royalty Pharma Q2 Earnings

Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 26.26% year over year to $0.73, which beat th...

2 months ago - Benzinga

Royalty Pharma Reports Second Quarter 2021 Results

NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipt...

2 months ago - GlobeNewsWire

Earnings Preview: Royalty Pharma (RPRX) Q2 Earnings Expected to Decline

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U....

3 months ago - GlobeNewsWire

Royalty Pharma Declares Third-Quarter 2021 Dividend

NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary...

3 months ago - GlobeNewsWire

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collec...

3 months ago - GlobeNewsWire

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June:

4 months ago - GlobeNewsWire

Royalty Pharma Insights: Return On Capital Employed

Royalty Pharma (NASDAQ:RPRX) posted a 26.99% decrease in earnings from Q4. Sales, however, increased by 0.18% over the previous quarter to $573.03 million.

4 months ago - Benzinga

MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma

MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of $1.7 billion. The transaction is expected to...

Other symbols:MOR
4 months ago - Benzinga

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership...

4 months ago - GlobeNewsWire

Royalty Pharma Reports First Quarter 2021 Results

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(...

5 months ago - GlobeNewsWire

Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021

NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S. finan...

6 months ago - GlobeNewsWire

Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes

NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and serv...

6 months ago - GlobeNewsWire

Royalty Pharma Declares Second-Quarter 2021 Dividend

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share.

6 months ago - GlobeNewsWire

SYF or RPRX: Which Is the Better Value Stock Right Now?

SYF vs. RPRX: Which Stock Is the Better Value Option?

6 months ago - Zacks Investment Research

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront

Royalty Pharma plc (NASDAQ: RPRX) has acquired  Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in c...

Other symbols:DRNA
6 months ago - Benzinga

Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million

NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that R...

6 months ago - GlobeNewsWire

Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK

Royalty Pharma Plc (NASDAQ: RPRX) has acquired a royalty interest in Cabometyx and Cometriq from GlaxoSmithKline Plc (NYSE: GSK) for an upfront payment of $342 million. Under this transaction's terms, R...

Other symbols:GSK
6 months ago - Benzinga